A practical approach to torsade de pointes

Clinical Cardiology

Volumn 20, Issue 3, 1997, Pages 285-290

  Roden, Dan M ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

long QT syndrome; proarrhythmia; torsade de pointes

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CENTRAL NERVOUS SYSTEM AGENTS; CISAPRIDE; ISOPRENALINE; KETANSERIN; LIDOCAINE; MAGNESIUM SULFATE; MEXILETINE; POTASSIUM; POTASSIUM CHANNEL STIMULATING AGENT; PROBUCOL; TERODILINE;

ELECTROCARDIOGRAPHY; HEART BLOCK; HEART PACING; HUMAN; HYPOKALEMIA; LONG QT SYNDROME; QT INTERVAL; REVIEW; TORSADE DES POINTES;

EID: 0030972504     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960200318     Document Type: Review

References (45)

1. Lewis T, Drury AN, Wedd AM, Iliescu CC: Observations upon the action of certain drugs upon fibrillation of the auricles. Heart 1922; 9:207-267
2. Jervell A, Lange-Nielsen F: Congenital deaf-mutism, functional heart disease with prolonaation of the Q-T interval and sudden death. Am Heart J 1957;54:59-68
3. Romano C, Gemme G, Pongiglione R: Aritmie cardiache rare in eta' pediatrica. Clin Pediatr 1963;45:656-683
4. Ward OC: A new familial cardiac syndrome in children. J Irish MedAssoc 1964;54:103-106
5. Selzer A, Wray HW: Quinidine syncope, paroxysmal ventricular fibrillations occurring during treatment of chronic atrial arrhythmias. Circulation 1964;30:17-30
6. Dessertenne F: La tachycardie ventriculaire à deux foyers opposés variables. Arch Mal Coeur 1966;59:263-272
7. Zwillinger L: Über die Magnesiumwirkung auf das Herz. Klin Wochenchr 1935;40:1429-1433
8. Horowitz LN, Greenspan AM, Spielman SR, Josephson ME: Torsade de pointes: Electrophysiologic studies in patients without transient pharmacologie or metabolic abnormalities. Circulation 1981; 63:1120-1128
9. Wolfe CL, Nibley C, Bhandari A, Chatterjee K, Scheinman M: Polymorphous ventricular tachycardia associated with acute myocardial infarction. Circulation 1991;84:1543-1551
10. Koster RW, Wellens HJJ: Quinidine-induced ventricular flutter and fibrillation without diaitalis therapy. Am J Cardiol 1976;38: 519-523
11. Bauman JL, Bauernfeind RA, Hoff JV, Strasberg B, Swiryn S, Rosen KM: Torsade de pointes due to quinidine: Observations in 31 vautnte. Am Heart J 1984; 107:425-430
12. Roden DM, Woosley RL, Primm RK: Incidence and clinical features of the quinidine-associated long QT syndrome: Implications for patient care. Am Heart J 1986; 111:1088-1093
13. Roden DM, Lazzara R, Rosen MR, Schwanz PJ, Vincent GM, for the SADS Foundation Task Force on LQTS: Multiple mechanisms in the long QT syndrome: Current knowledge, gaps, and future directions. Circulation 1996;94:1996-2012.
14. Wang Q, Shen J, Li Z, Timothy K, Vincent GM, Priori SG, Schwanz PJ, Keating MT: Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia. Hum Molec Gen 1995;4:1603-1607
15. Bennett PB, Yazawa K, Makita N, George AL Jr: Molecular mechanism for an inherited cardiac arrhythmia. Nature 1995;376: 683-685
16. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT: A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995:80:795-803
17. Wang Q, Curran ME, Splawski I, Burn TC, Millholland JM, VanRaay TJ, Shen J, Timothy KW, Vincent GM, de Jager T, Schwanz PJ, Towbin JA, Moss AJ, Atkinson DL, Landes GM, Connors TD, Keating MT: Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nature Genetics 1996; 12:17-23
18. Roden DM: Current status of class III antiarrhythmic therapy. Am J Cardiol 1993;72:44B-49B
19. ks: Implications for torsade de pointes and reverse use-dependence. Circulation 1996;93:407-411
20. + currents. Pflügers Arch 1992; 420:180-186
21. Campbell RW, Furniss SS: Practical considerations in the use of sotalol for ventricular tachycardia and ventricular fibrillation. Am J Cardiol 1993;72:80A-85A
22. Hii JT, Wyse DG, Gillis AM, Duff HJ, Solylo MA, Mitchell LB: Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class la antiarrhythmic drugs and amiodarone. Circulation 1992;86:1376-1382
23. Antzelevitch C, Sicouri S: Clinical relevance of cardiac arrhythmias generated by afterdepolarizations: The role of M cells in the generation of U waves, triggered activity and torsade de pointes. J Am Coll Cardiol 1994;23:259-277
24. Kay GN, Plumb VJ, Arciniegas JG, Henthom RW, Waldo AL: Torsade de pointes: The long-short initiating sequence and other clinical features: Observations in 32 patients. J Am Coll Cardiol 1983:2:806-817
25. Locati EH, Maison-Blanche P, Dejode P, Cauchemez B, Coumel P: Spontaneous sequences of onset of torsade de pointes in patients with acquired prolonged repolarization: Quantitative analysis of Holier recordings. JAm Coll Cardiol 1995;25:1564-1575
26. Wiesfeld AC, Crijns HJ, Bergstrand RH, Almgren O, Hillege HL, Lie Kl: Torsade de pointes with Almokalant, a new class III antiarrhythmic drug. Am Heart J 1993; 126:1008-1011
27. Bazett HC: An analysis of the time relations of electrocardiograms. Heart 1920;7:353-370
28. Mattioni TA, Zheutlin TA, Sarmiento JJ, Parker M, Lesch M, Kehoe RF: Amiodarone in patients with previous drug-mediated torsade de pointes. Ann Intern Med 1989; 111:574-580
29. Lazzara R: Amiodarone and torsade de pointes. Ann Intern Med 1989;111:549-551
30. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH: Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. J Am MedAssoc 1993;270:2590-2597
31. Vincent GM, Timothy KW, Leppert M, Keating M: The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome. NEngUMed 1992;327:846-852
32. Choy AMJ, Darbar D, Dell'Orto S, Roden DM: Increased sensitivity to QT prolonging drug therapy immediately after cardioversion to sinus rhythm. Circulation 1996;94:1202
33. Hohnloser SH, Arendts W, Quart B, Bristol Myers Squibb Research Institute: Incidence, type, and dose-dependence of proarrhythmic events during sotalol therapy in patients treated for sustained VT/VF (abstr). PA CE 1992;15:551
34. Hohnloser SH, Woosley RL: Sotalol. N Engl J MeD 1994;331: 31-38
35. Chovv MJ, Piergies AA, Bowsher DJ, Murphy JJ, Kushner W, Ruo TI, Asada A, Talano J V, Atkinson AJ: Torsade de pointes induced by N-acety Iprocainamide. J Am Call Canliol 1984;4:621-624
36. Slambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, VanderLugt JT, The Ibulilide Repeat Dose Study Investigators: Efficacy and safety of repeated intravenous doses of ibutilidc for rapid conversion of atrial flutter or fibrillation. Circulation 1996; 94:1613-1621
37. Roden DM: Ibutilide and the treatment of atrial arrhythmias: A new drug - almost unheralded - is now available to US physicians. Circulation 1996;94:1499-1502
38. Woosley RL, Chen Y, Freiman JP, Gillis RA: Mechanism of the cardiotoxic actions of terfenadine. J Am Metl Assoc 1993;269: 1532-1536
39. Roy ML, Dumaine R, Brown AM: HERO, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation 1996;94:817-823
40. Roden DM, George AL Jr, Bennett PB: Recent advances in understanding the molecular mechanisms of the long QT syndrome. J Canliuvasc Eleawphysiol 1995 ;6:1023-1031
41. Carlsson L, Abrahamsson C, Andersson B, Duker G, Schiller-Linhardt G: Proarrhythmic effects of the class III agent almokalant: Importance of infusion rate, QT dispersion, and early afterdepolarisations. Canliovasc Res 1993;27:2186-2193
42. Brachmann J, Scherlag BJ, Rosenshtraukh LV, Lazzara R: Bradycardia-dependent triggered activity: Relevance to drug-induced multiform ventricular tachycardia. Circulation 1983;68:846-856
43. Roden DM, Hoffman BF: Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers. Relationship to potassium and cycle lensth. Circ Res 1985;56:857-867
44. Tzivoni D, Banai S, Schugar C, Benhorin J; Keren A, Gottlieb S, Stern S: Treatment of torsade de pointes with magnesium sulfate. Circulation 1988;77:392-397
45. Schwartz PJ, Zaza A, Locati E.Moss AJ: Stress and sudden death. The case of the long QT syndrome. Circulation 1991;83:I171-I180